share_log

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

Benzinga ·  Nov 7 07:36  · Ratings

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $90 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment